Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Accumulated Depreciation (2016)

Cartesian Therapeutics (RNAC) has disclosed Accumulated Depreciation for 2 consecutive years, with $3.3 million as the latest value for Q2 2016.

  • On a quarterly basis, Accumulated Depreciation changed N/A to $3.3 million in Q2 2016 year-over-year; TTM through Jun 2016 was $3.3 million, a N/A change, with the full-year FY2015 number at $2.9 million, changed N/A from a year prior.
  • Accumulated Depreciation was $3.3 million for Q2 2016 at Cartesian Therapeutics, up from $2.9 million in the prior quarter.
  • In the past five years, Accumulated Depreciation ranged from a high of $3.3 million in Q2 2016 to a low of $2.9 million in Q4 2015.